Zhitong Finance App News, Shanghai Pharmaceutical (02607) announced that in order to rationally allocate R&D resources and focus on advantageous R&D projects, the company decided to terminate clinical trials and subsequent development of I025-A R&D projects based on a comprehensive evaluation of factors such as future market value, business collaboration, and subsequent development investment of R&D projects.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.